Artal Group’s Ionis Pharmaceuticals IONS Stock Holding History

Artal Group’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-135,000	Closed	-$6.87M	–	116
2017 Q2	$6.87M	Sell	135,000 -115,000	-46%	-$5.36M	0.12%	47
2017 Q1	$10.1M	Buy	+250,000	New	+$11.2M	0.22%	42
2016 Q2	–	Sell	-350,000	Closed	-$14.2M	–	75
2016 Q1	$14.2M	Hold	350,000	–	–	0.28%	25
2015 Q4	$21.7M	Sell	350,000 -50,000	-13%	-$2.7M	0.41%	31
2015 Q3	$16.2M	Hold	400,000	–	–	0.36%	38
2015 Q2	$23M	Hold	400,000	–	–	0.99%	31
2015 Q1	$25.5M	Sell	400,000 -5,000	-1%	-$339K	1.18%	22
2014 Q4	$25M	Sell	405,000 -50,000	-11%	-$2.47M	0.88%	27
2014 Q3	$17.7M	Hold	455,000	–	–	0.65%	28
2014 Q2	$15.7M	Buy	455,000 +355,000	+355%	+$11.2M	0.63%	36
2014 Q1	$4.32M	Buy	+100,000	New	+$4.85M	0.16%	76

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Artal Group's IONS Position: Q3 2017 in Review

Artal Group sold out of Ionis Pharmaceuticals (IONS) in Q3 2017, closing a stake of 135,000 shares — an estimated $6.87M sold.

Artal Group first reported a position in IONS in Q1 2014 and held it in 11 quarters. The position peaked at $25.5M in Q1 2015. 301 funds tracked by Wall St. Rank hold IONS as of Q3 2017.

Artal Group reported no remaining Ionis Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Artal Group sold 135,000 Ionis Pharmaceuticals shares in Q3 2017, an estimated $6.87M.
Artal Group first reported a position in Ionis Pharmaceuticals in Q1 2014 and held it in 11 quarters.
Artal Group's Ionis Pharmaceuticals position peaked at $25.5M in Q1 2015.
301 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2017.

Based on Artal Group's 13F filing for Q3 2017, filed 8 Nov 2017.